4D Molecular Therapeutics Inc (NASDAQ:FDMT) currently has a daily average trading volume of 842.99K but it saw 1482167 shares traded in last market. With a market cap of 957.48M USD, the company’s current market price of $18.52 came rising about 3.23 while comparing to the previous closing price of $17.94. In past 52 weeks, the stock remained buoying in the range of price level as high as $36.25 and as low as $9.44.
Taking a look at 20-day trading activity of 4D Molecular Therapeutics Inc (FDMT) gives us an average price of $20.96, while its current price level is -48.91% below from 52-week high level whereas it is 96.19% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $22.90 while that of 200 days or SMA-200 reads an average of $21.41. A closer look into the stock’s movement over the week reveals that its volatility is standing at 11.28% during that period while stretching the period over a month that decreases to 11.00%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 42.19 which implies that the stock is in neutral territory.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the Barclays which initiated the stock as “Overweight” in its note to investors issued on April 15, 2024, recommending a price target of $459 for it. Goldman issued its recommendations for the stock as it resumed the price target for the stock is $81.
Over the week, FDMT’s stock price is moving 22.32% up while it is -15.82% when we observe its performance for the past one month. Year-to-date it is -8.59% down and over the past year, the stock is showing an upside performance of 2.83%.
Currently, 4D Molecular Therapeutics Inc’s total number of outstanding shares is 51.70M. Company’s return on investment (ROI) stands at -15.69% and return on equity (ROE) at -33.00%. Stock’s beta reads 2.84. Stock has a price to book (P/B) ratio of 1.58 while price to sale or P/S ratio amounts to 43.54. Its return on asset (ROA) is -29.90% on average.
